DA Davidson cuts Phreesia stock price target on revenue assumptions
DA Davidson reduced its price target for Phreesia Inc. (NYSE:PHR) to $13.00 from $14.00, citing adjusted revenue assumptions and growth timelines. The firm maintained a Buy rating, noting mixed Q2 fiscal 2027 results with revenue of $129.5M and adjusted EBITDA of $32.9M. Phreesia's stock trades at $10.92, below analyst consensus targets ranging from $10 to $20.
How this was made
The 30-second read
Why it matters
Analyst target reduction reflects concerns over subscription growth, despite positive network solutions trends.
Market read
The downgrade adds pressure on Phreesia's stock and may influence sentiment in the broader health‑tech niche.
What to watch
Higher network solutions contributions and potential upside from AccessOne could offset slower subscription growth.
Background
Phreesia reported Q2 FY2027 results with revenue slightly above estimates but earnings per share missed forecasts.
Ticker impact
DA Davidson lowered Phreesia's price target to $13, citing slower revenue growth and revised subscription assumptions.
Potential downside of 3-5% over the next few days.
Analyst downgrade after earnings often triggers sell pressure, especially when the new target is below current price.
Market effects
Healthcare software sector may see modest re‑rating as analysts reassess growth timelines.
U.S. market impact limited to small‑cap healthcare tech stocks.
Minimal global effect beyond niche investors.
Counterpoint
The price target cut may be overly cautious given the company's expanding network solutions revenue.
Key entities
- companyPhreesia Inc.
Healthcare software provider.
- analystDA Davidson
Equity research firm issuing the price target cut.
